PolyActiva and RareSight have announced a “strategic collaboration” to develop first-in-class therapies for rare pediatric retinal diseases with no current approved drug treatments.

Patients with glaucoma who are using prostaglandin F (FP) receptor agonists to control their disease may experience accelerated progression of presbyopia

A 15-year-old boy developed myopia at 8 years and was treated with 0.01% atropine daily in both eyes. The atropine dose was increased yearly as the myopia progressed.

The challenge is to identify drugs and associated substances that do not cause adverse effects or complications in pediatric patients with GDD implants.

Clinical-stage medical technology company EyeCool Therapeutics, based in Cambridge, Massachusetts, has announced positive results from a pilot study on its investigational ETX-4143 device for the treatment of chronic ocular surface pain (COSP).

A research team from Turkey, led by Dr. Oğuzhan Kılıçarslan (FEBO, FICO), has reported that COVID-19 affects the morphology of corneal endothelial cells in patients with ocular symptoms.

A new study shows that Paclitaxel, a drug used for the treatment of breast cancer, can, in very rare cases, cause a serious complication known as Central Retinal Artery Occlusion (CRAO)....

Chinese researchers have demonstrated that repeated low-level red light (RLRL) therapy can effectively control the progression of myopia in children.